Series A investment in the Danish biotech company Antag Therapeutics to advance novel obesity treatments

Mazanti Transactions advised a group of investors on their participation in the EUR 80 million Series A financing of Danish Antag Therapeutics. The round was led by Versant Ventures, with participation from Novo Holdings, SR One, Dawn Biopharma, Pictet, Longview Ventures, and EIFO (Denmark’s Export and Investment Fund).

Antag Therapeutics, founded in 2017 and headquartered in Copenhagen, Denmark, is a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies for obesity and cardiometabolic diseases through GIP receptor antagonism.

The funding will support the clinical development of the company’s lead candidate, AT-7687, a novel, once-weekly subcutaneous antagonist of the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR), and also fueling the expansion of Antag's pipeline of monthly injectable therapies.

Mazanti Transactions advised a group of investors on all aspects of the investment in Antag Therapeutics with a team led by Lars Lüthjohan.